Washington University - Seattle
Welcome,         Profile    Billing    Logout  
 17 Trials 
44 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chugh, Rashmi
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
EZH-301, NCT04204941 / 2019-003648-55: Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Checkmark Early data from P1b/3 trial for advanced epithelioid sarcoma at medical conference 2021
May 2021 - May 2021: Early data from P1b/3 trial for advanced epithelioid sarcoma at medical conference 2021
Recruiting
3
164
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Doxorubicin HCl, Tazverik®, Placebo
Epizyme, Inc.
Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma
01/29
01/30
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
06/24
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
NCT04076579: Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Active, not recruiting
2
29
US
Olaparib, Trabectedin
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC, AstraZeneca
Sarcoma, Sarcoma Metastatic
01/23
01/25
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
APOLLO 613, NCT04593758: To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Completed
1/2
16
US
CPI-613 + Hydroxychloroquine
Cornerstone Pharmaceuticals
Sarcoma, Clear Cell
03/23
03/23
NCT02584647: PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Active, not recruiting
1/2
43
US
PLX3397, No other name, Sirolimus, Rapamune
Gulam Manji, Daiichi Sankyo
Sarcoma, Malignant Peripheral Nerve Sheath Tumors
07/23
06/24
SARC037, NCT04067115: a Phase I/II Study to Evaluate the Safety of Trabectedin in Combination with Irinotecan in Ewing Sarcoma Patients

Active, not recruiting
1/2
48
US
Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging, 18F-FLT Imaging
Sarcoma Alliance for Research through Collaboration, Janssen Scientific Affairs, LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)
Ewing Sarcoma
06/25
06/25
KB-0742-1001, NCT04718675: A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Active, not recruiting
1/2
280
Europe, US
KB-0742
Kronos Bio
Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma, HGSOC, Platinum Resistant High Grade Serous Ovarian Cancer
12/25
12/25
LiFFT, NCT05918640: Lurbinectedin in FET-Fused Tumors

Recruiting
1/2
56
US
Lurbinectedin
Children's Hospital of Philadelphia, Jazz Pharmaceuticals, Stand Up To Cancer
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
07/26
07/28
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
ADP adoptive cell therapy
Adaptimmune
Neoplasms
04/32
04/32
Cranmer, Lee D
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
FIBROSARC USA, NCT03420014: Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients

Recruiting
2
114
US
Doxorubicin, L19TNF plus doxorubicin
Philogen S.p.A.
Leiomyosarcoma
12/24
12/25
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
NCI-2018-01624, NCT03660930: Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Active, not recruiting
1/2
19
US
Sirolimus Albumin-bound Nanoparticles, Nab-Rapamycin, Nanoparticle Albumin-Bound Rapamycin, ABI-009, Nanoparticle Albumin-bound Sirolimus, Fyarro, Sirolimus Protein-bound Particles, Pazopanib hydrochloride, Votrient
University of Washington, Aadi Bioscience, Inc.
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
11/22
02/25
NCT03338959: Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma

Completed
1/2
27
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, NOS, Energy Type
Fred Hutchinson Cancer Center, Merck Sharp & Dohme LLC
Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
06/23
08/23
NCT04220229: Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Terminated
1/2
6
US
Cabozantinib S-malate, 1140909-48-3, BMS-907351, Butanedioic acid, Cabometyx, Cometriq, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, Irradiation, RADIATION, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
University of Washington, Exelixis
Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities
04/24
10/24
NCI-2018-00615, NCT03670069: Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Terminated
1
27
US
Itacitinib, 1334298-90-6, 3-Azetidineacetonitrile, INCB039110, Laboratory Biomarker Analysis
Fred Hutchinson Cancer Center, Incyte Corporation
Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Refractory Leiomyosarcoma, Refractory Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Chondrosarcoma
03/23
05/24
SALA-002-EW16, NCT03600649: Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Active, not recruiting
1
50
US
Seclidemstat, LSD1 Inhibitor, SP-2577, Cyclophosphamide, Topotecan
Salarius Pharmaceuticals, LLC, National Pediatric Cancer Foundation
Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Primary Pulmonary Myxoid Sarcoma, Myoepithelial Tumor, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor
09/25
12/25
NCT06025747: Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma

Recruiting
1
18
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Therapeutic Surgical Procedure
Fred Hutchinson Cancer Center, Eli Lilly and Company
Retroperitoneal Sarcoma
03/25
03/26
Wagner, Michael
SARC041, NCT04967521: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

Active, not recruiting
3
108
US
Abemaciclib, LY2835219, Placebo
Sarcoma Alliance for Research through Collaboration, Eli Lilly and Company
Advanced Dedifferentiated Liposarcoma
12/25
12/26
SPEARHEAD-1, NCT04044768 / 2019-000589-39: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Oct 2022 - Jun 2023: BLA submission for treatment of synovial sarcoma
Checkmark Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Nov 2022 - Nov 2022: Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Checkmark Pooled analysis data from trials for sarcoma at AACR 2022
Jun 2022 - Jun 2022: Pooled analysis data from trials for sarcoma at AACR 2022
More
Active, not recruiting
2
52
Europe, Canada, US
afamitresgene autoleucel (previously ADP-A2M4)
Adaptimmune, Adaptimmune LLC
Synovial Sarcoma, Myxoid Liposarcoma
08/21
04/38
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCI-2018-00615, NCT03670069: Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Terminated
1
27
US
Itacitinib, 1334298-90-6, 3-Azetidineacetonitrile, INCB039110, Laboratory Biomarker Analysis
Fred Hutchinson Cancer Center, Incyte Corporation
Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Refractory Leiomyosarcoma, Refractory Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Chondrosarcoma
03/23
05/24
NCT06414434: BTX-A51 in Patients With Liposarcoma

Recruiting
1
12
US
BTX-A51, C32H41ClN6O6S2, (1r,4r)-N 1-(5-chloro-4-(5-(cyclopropylmethyl)-1-methyl-l H pyrazol-3-yl)pyrimidin-2-yl)cyclohexane-l ,4-diamine bis(4-methylbenzenesulfonate),
Michael Wagner, MD, Edgewood Oncology Inc.
Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma, MDM2 Gene Amplification
06/26
06/27
FHD-609-C-001, NCT04965753 / 2021-001488-25: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Terminated
1
55
Europe, US
FHD-609
Foghorn Therapeutics Inc., Foghorn Therapeutics Inc.
Advanced Synovial Sarcoma
12/23
12/23
NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, Merck Sharp & Dohme LLC
Solid Tumor
12/31
12/31
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
ADP adoptive cell therapy
Adaptimmune
Neoplasms
04/32
04/32
NCT06617572: Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

Available
N/A
US
Non-conforming afamitresgene autoleucel
Adaptimmune
Synovial Sarcoma, Myxoid Liposarcoma
 
 
NCT04255966: Plasmafit® Revision Structan® Hip Endoprosthesis Cup

Active, not recruiting
N/A
60
Europe
Plasmafit® Revision Structan®
Aesculap AG
Osteolysis, Arthroplasty Complications, Instability of Prosthetic Joint, Degenerative Osteoarthritis, Rheumatic Arthritis, Fractures, Hip, Femoral Head Avascular Necrosis, Prosthesis Failure
08/23
06/27
US-Lung AI-11237, NCT04891705: Point of Care Ultrasound Lung Artificial Intelligence (AI) Validation Data Collection Study

Completed
N/A
554
US
Lung Ultrasound Scan
Philips Clinical & Medical Affairs Global
Pleural Effusion, Lung Consolidation
12/23
12/23
Moore, Roxanne
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCI-2018-01624, NCT03660930: Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Active, not recruiting
1/2
19
US
Sirolimus Albumin-bound Nanoparticles, Nab-Rapamycin, Nanoparticle Albumin-Bound Rapamycin, ABI-009, Nanoparticle Albumin-bound Sirolimus, Fyarro, Sirolimus Protein-bound Particles, Pazopanib hydrochloride, Votrient
University of Washington, Aadi Bioscience, Inc.
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
11/22
02/25
NCT03338959: Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma

Completed
1/2
27
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, NOS, Energy Type
Fred Hutchinson Cancer Center, Merck Sharp & Dohme LLC
Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
06/23
08/23
NCT04220229: Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Terminated
1/2
6
US
Cabozantinib S-malate, 1140909-48-3, BMS-907351, Butanedioic acid, Cabometyx, Cometriq, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, Irradiation, RADIATION, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
University of Washington, Exelixis
Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities
04/24
10/24
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
01/25
01/25
NCI-2018-00615, NCT03670069: Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Terminated
1
27
US
Itacitinib, 1334298-90-6, 3-Azetidineacetonitrile, INCB039110, Laboratory Biomarker Analysis
Fred Hutchinson Cancer Center, Incyte Corporation
Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Refractory Leiomyosarcoma, Refractory Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Chondrosarcoma
03/23
05/24
NCT05043649: Camsirubicin + Pegfilgrastim to Determine MTD in ASTS

Terminated
1
14
US
Camsirubicin
Monopar Therapeutics
Advanced Soft-tissue Sarcoma
10/23
05/24
SALA-002-EW16, NCT03600649: Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Active, not recruiting
1
50
US
Seclidemstat, LSD1 Inhibitor, SP-2577, Cyclophosphamide, Topotecan
Salarius Pharmaceuticals, LLC, National Pediatric Cancer Foundation
Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Primary Pulmonary Myxoid Sarcoma, Myoepithelial Tumor, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor
09/25
12/25
NCT06025747: Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma

Recruiting
1
18
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Therapeutic Surgical Procedure
Fred Hutchinson Cancer Center, Eli Lilly and Company
Retroperitoneal Sarcoma
03/25
03/26
NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, Merck Sharp & Dohme LLC
Solid Tumor
12/31
12/31
Steibel, Jolene
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26

Download Options